These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27812955)

  • 1. Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.
    Stavre Z; Upchurch K; Kay J; Gravallese EM
    Curr Rheumatol Rep; 2016 Dec; 18(12):72. PubMed ID: 27812955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of targeted therapies on the bone in arthritides.
    Szentpétery Á; Horváth Á; Gulyás K; Pethö Z; Bhattoa HP; Szántó S; Szücs G; FitzGerald O; Schett G; Szekanecz Z
    Autoimmun Rev; 2017 Mar; 16(3):313-320. PubMed ID: 28159704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal bone involvement in inflammatory arthritis: the role of IL17.
    Rossini M; Viapiana O; Adami S; Idolazzi L; Fracassi E; Gatti D
    Rheumatol Int; 2016 Apr; 36(4):469-82. PubMed ID: 26521079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
    Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.
    Soós B; Szentpétery Á; Raterman HG; Lems WF; Bhattoa HP; Szekanecz Z
    Nat Rev Rheumatol; 2022 May; 18(5):249-257. PubMed ID: 35273387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations.
    Schett G
    Am J Med Sci; 2011 Apr; 341(4):269-71. PubMed ID: 21358309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Biggioggero M; Benucci M; Li Gobbi F; Grossi V; Infantino M; Meacci F; Manfredi M; Guiducci S; Bellando-Randone S; Matucci-Cerinic M; Foti R; Di Gangi M; Mosca M; Tani C; Palmieri F; Goletti D;
    Semin Arthritis Rheum; 2016 Apr; 45(5):519-32. PubMed ID: 26607440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 11. Structural Disease Progression in Axial Spondyloarthritis: Still a Cause for Concern?
    Neerinckx B; Lories RJ
    Curr Rheumatol Rep; 2017 Mar; 19(3):14. PubMed ID: 28265849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local synovial engagement of angiogenic TIE-2 is associated with the development of persistent erosive rheumatoid arthritis in patients with early arthritis.
    van de Sande MG; de Launay D; de Hair MJ; García S; van de Sande GP; Wijbrandts CA; Gerlag DM; Reedquist KA; Tak PP
    Arthritis Rheum; 2013 Dec; 65(12):3073-83. PubMed ID: 23982963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone effects of biologic drugs in rheumatoid arthritis.
    Corrado A; Neve A; Maruotti N; Cantatore FP
    Clin Dev Immunol; 2013; 2013():945945. PubMed ID: 23864880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis.
    Goldring SR
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii56-ii60. PubMed ID: 27856661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs.
    Michel M; Vincent FB; Rio S; Leon N; Marcelli C
    Joint Bone Spine; 2016 Mar; 83(2):237-8. PubMed ID: 26190453
    [No Abstract]   [Full Text] [Related]  

  • 17. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
    Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
    Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsteroidal Antiinflammatory Drugs as Potential Disease-Modifying Medications in Axial Spondyloarthritis.
    Wang R; Bathon JM; Ward MM
    Arthritis Rheumatol; 2020 Apr; 72(4):518-528. PubMed ID: 31705611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.
    Poddubnyy D; Gensler LS
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):807-18. PubMed ID: 25488786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spondyloarthritis: from unifying concepts to improved treatment.
    Paramarta JE; Baeten D
    Rheumatology (Oxford); 2014 Sep; 53(9):1547-59. PubMed ID: 24369419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.